KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $26000.0.

  • Esperion Therapeutics' Depreciation & Amortization (CF) changed 0.0% to $26000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $143000.0, marking a year-over-year increase of 8333.33%. This contributed to the annual value of $100000.0 for FY2024, which is 5000.0% down from last year.
  • Esperion Therapeutics' Depreciation & Amortization (CF) amounted to $26000.0 in Q3 2025, which was down 0.0% from $27000.0 recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Depreciation & Amortization (CF) registered a high of $153000.0 during Q1 2021, and its lowest value of $10000.0 during Q2 2024.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $72500.0 (2023), whereas its average is $82833.3.
  • Per our database at Business Quant, Esperion Therapeutics' Depreciation & Amortization (CF) plummeted by 8039.22% in 2024 and then soared by 17000.0% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $153000.0 in 2021, then crashed by 39.87% to $92000.0 in 2022, then plummeted by 54.35% to $42000.0 in 2023, then skyrocketed by 52.38% to $64000.0 in 2024, then crashed by 59.38% to $26000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $26000.0 in Q3 2025, compared to $27000.0 in Q2 2025 and $26000.0 in Q1 2025.